Cormedix(DE:19KA)
€4.16+0.14 (+3.58%)
DE:19KA
Cormedix financials statements
€4.16
At close:+0.14 (+3.58%)
Cormedix (19KA) Ratios
2 Followers
Cormedix Ratios
DE:19KA's free cash flow for Q3 2026 was $87.79M. For the 2026 fiscal year, DE:19KA's free cash flow was decreased by $-1.91M and operating cash flow was $89.70M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.11 | 3.39 | 6.97 | 9.44 | 12.44 |
| Quick Ratio | 1.94 | 3.16 | 6.78 | 9.44 | 12.43 |
| Cash Ratio | 0.84 | 1.20 | 3.83 | 6.87 | 9.98 |
| Solvency Ratio | 0.42 | -0.52 | -3.88 | -4.23 | -4.56 |
| Operating Cash Flow Ratio | 1.00 | -1.50 | -3.37 | -3.86 | -3.96 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -53.78M | $ 80.39M | $ 67.53M | $ 52.57M | $ 60.32M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.18 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.37 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.27 | 0.01 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.04 | 1.40 | 1.17 | 1.13 | 1.10 |
| Debt Service Coverage Ratio | 64.84 | -483.01 | 0.00 | -1111.30 | -1764.13 |
| Interest Coverage Ratio | 53.97 | -614.10 | 0.00 | -1154.97 | -1846.43 |
| Debt to Market Cap | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 2.11 | 0.01 | 0.01 | 0.02 | 0.02 |
| Net Debt to EBITDA | 0.02 | 2.11 | 0.93 | 1.42 | 1.78 |
| Profitability Margins | |||||
| Gross Profit Margin | 88.46% | 92.66% | 0.00% | 94.29% | 22.00% |
| EBIT Margin | 49.02% | -44.37% | 0.00% | -46264.69% | -15421.12% |
| EBITDA Margin | 53.69% | -43.66% | 0.00% | -45945.10% | -15385.10% |
| Operating Profit Margin | 48.17% | -51.43% | 0.00% | -46819.91% | -15417.51% |
| Pretax Profit Margin | 48.13% | -44.45% | 0.00% | -46305.23% | -15429.47% |
| Net Profit Margin | 52.31% | -41.24% | 0.00% | -45409.90% | -14774.70% |
| Continuous Operations Profit Margin | 52.31% | -41.24% | 0.00% | -45409.90% | -14774.70% |
| Net Income Per EBT | 108.69% | 92.78% | 100.00% | 98.07% | 95.76% |
| EBT Per EBIT | 99.92% | 86.44% | 94.65% | 98.90% | 100.08% |
| Return on Assets (ROA) | 19.74% | -15.09% | -56.47% | -47.88% | -40.92% |
| Return on Equity (ROE) | 40.23% | -21.18% | -66.06% | -53.94% | -44.92% |
| Return on Capital Employed (ROCE) | 23.03% | -26.30% | -69.29% | -54.95% | -46.29% |
| Return on Invested Capital (ROIC) | 22.98% | -24.35% | -69.14% | -53.76% | -44.24% |
| Return on Tangible Assets | 39.10% | -15.32% | -56.47% | -47.88% | -40.92% |
| Earnings Yield | 19.46% | -3.76% | -24.21% | -17.54% | -16.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.82 | 0.84 | 0.00 | 0.00 | 4.21 |
| Payables Turnover | 4.56 | 1.85 | 0.05 | 0.00 | 0.07 |
| Inventory Turnover | 1.21 | 0.42 | 0.10 | 0.00 | 49.51 |
| Fixed Asset Turnover | 31.41 | 18.73 | 0.00 | 0.03 | 0.08 |
| Asset Turnover | 0.38 | 0.37 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 2.28 | 0.58 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 422.10 | 1106.30 | -3859.02 | -215260.95 | -5320.82 |
| Days of Sales Outstanding | 200.51 | 433.69 | 0.00 | 0.00 | 86.73 |
| Days of Inventory Outstanding | 301.61 | 869.39 | 3740.07 | 0.00 | 7.37 |
| Days of Payables Outstanding | 80.02 | 196.79 | 7599.08 | 215260.95 | 5414.91 |
| Operating Cycle | 502.12 | 1303.09 | 3740.07 | 0.00 | 94.10 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.43 | -0.86 | -0.75 | -0.61 | -0.56 |
| Free Cash Flow Per Share | 2.40 | -0.86 | -0.76 | -0.61 | -0.60 |
| Dividend Paid and CapEx Coverage Ratio | 77.45 | -437.35 | -117.35 | -111.04 | -14.84 |
| Capital Expenditure Coverage Ratio | 77.45 | -437.35 | -117.35 | -111.04 | -14.84 |
| Operating Cash Flow Coverage Ratio | 1.18 | -97.90 | -57.53 | -30.35 | -22.90 |
| Operating Cash Flow to Sales Ratio | 0.56 | -1.16 | 0.00 | -372.38 | -110.80 |
| Free Cash Flow Yield | 20.62% | -10.64% | -20.24% | -14.51% | -13.19% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 5.17 | -26.60 | -4.13 | -5.70 | -6.07 |
| Price-to-Sales (P/S) Ratio | 2.69 | 10.97 | 0.00 | 2589.59 | 896.33 |
| Price-to-Book (P/B) Ratio | 2.07 | 5.63 | 2.73 | 3.08 | 2.73 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 4.85 | -9.40 | -4.94 | -6.89 | -7.58 |
| Price-to-Operating Cash Flow Ratio | 4.79 | -9.42 | -4.98 | -6.95 | -8.09 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.40 | -0.18 | 4.28 | 2.34 |
| Enterprise Value Multiple | 5.02 | -23.01 | -3.21 | -4.22 | -4.04 |
| Enterprise Value | 840.84M | 436.73M | 148.42M | 126.81M | 118.75M |
| EV to EBITDA | 5.02 | -23.01 | -3.21 | -4.22 | -4.04 |
| EV to Sales | 2.70 | 10.05 | 0.00 | 1938.72 | 621.93 |
| EV to Free Cash Flow | 4.87 | -8.61 | -3.83 | -5.16 | -5.26 |
| EV to Operating Cash Flow | 4.80 | -8.63 | -3.86 | -5.21 | -5.61 |
| Tangible Book Value Per Share | -0.05 | 1.41 | 1.38 | 1.37 | 1.67 |
| Shareholders’ Equity Per Share | 5.63 | 1.44 | 1.38 | 1.37 | 1.67 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.09 | 0.07 | 0.00 | 0.02 | 0.04 |
| Revenue Per Share | 4.33 | 0.74 | 0.00 | 0.00 | 0.01 |
| Net Income Per Share | 2.26 | -0.30 | -0.91 | -0.74 | -0.75 |
| Tax Burden | 1.09 | 0.93 | 1.00 | 0.98 | 0.96 |
| Interest Burden | 0.98 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.06 | 0.09 | 0.00 | 163.28 | 68.78 |
| SG&A to Revenue | 0.10 | 1.35 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.04 | 0.14 | 0.00 | 62.22 | 26.41 |
| Income Quality | 1.07 | 2.82 | 0.83 | 0.82 | 0.75 |
Currency in USD

